[Fundamental and clinical studies on cefminox in the field of pediatrics].
Cefminox (CMNX, MT-141) is a new injectable cephamycin antibiotic, which was studied for its antibacterial activity, absorption and excretion after administration and clinical efficacy of patients with infections. The following results were obtained. Antibacterial activity The antibacterial activity of CMNX against 19 clinical isolates consisting of 11 species made the results that its activity against E. coli, P. vulgaris and C. jejuni was superior to CMZ and CEZ. Concentration in serum and urine CMNX was given intravenously to 3 groups at 20 mg/kg by one shot (2 cases), 40 mg/kg by one shot (2 cases) and 40 mg/kg by 1 hour drip infusion (1 case). The half-lives were between 1.15 to 1.80 hours. We obtained over 70% of its excretion to urine within 6 hours after injection. Clinical efficacy Clinical evaluation was made on a total of 18 patients with various infections, 11 of whom had underlying diseases. The result was excellent in 1 case, good in 11 cases, fair in 2 cases and poor in 4 cases, and the effective rate was 66.7%. Side effect Clinical and laboratory abnormal findings related to CMNX were not found. It is concluded that CMNX seems to be effective and safetive antibiotic in the field of pediatrics.
D000038:Abscess / Q000188:drug therapy; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002167:Campylobacter / Q000187:drug effects; D002169:Campylobacter Infections / Q000188:drug therapy; D002513:Cephamycins / Q000378:metabolism / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D005891:Gingivitis / Q000188:drug therapy; D006801:Humans; D007223:Infant; D008297:Male
D000900:Anti-Bacterial Agents; D002513:Cephamycins; C046079:cefminox